Showing results (51-60 of 292) with videos related to
Sort By:
Pageof 30
Expert Review of Pharmacoeconomics & Outcomes Research|May 12, 2015
Hurdles that impede economic evaluations of welfare interventionsJanne Schepers, Lieven Annemans, Steven SimoensJournal of Advanced Nursing|August 22, 2009
Search and destroy policy for methicillin-resistant Staphylococcus aureus: cost-benefit analysisSteven Simoens, Erik Ophals, Annette SchuermansExpert Review of Pharmacoeconomics & Outcomes Research|November 22, 2011
The impact of reference-pricing systems in Europe: a literature review and case studiesPieter Dylst, Arnold Vulto, Steven SimoensTargeted Oncology|January 18, 2012
Biosimilars and market access: a question of comparability and costs?Steven Simoens, Gilbert Verbeken, Isabelle HuysRespiratory Medicine|May 3, 2006
Economic aspects of antimicrobial therapy of acute exacerbations of COPDSteven Simoens, Marc Decramer, Gert LaekemanPharmacy Practice|September 13, 2014
Management of drug interactions with beta-blockers: continuing education has a short-term impactAnnelies Driesen, Steven Simoens, Gert LaekemanBiodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|December 28, 2020
Budget Impact Analysis of the Introduction of Rituximab and Trastuzumab Intravenous Biosimilars to EU-5 MarketsMinyoung Jang, Steven Simoens, Taeksang KwonOrphanet Journal of Rare Diseases|October 30, 2016
Off-label use of orphan medicinal products: a Belgian qualitative studyMarc Dooms, David Cassiman, Steven SimoensHealth Policy (Amsterdam, Netherlands)|April 23, 2011
Tendering for outpatient prescription pharmaceuticals: what can be learned from current practices in Europe?Pieter Dylst, Arnold Vulto, Steven SimoensExpert Review of Pharmacoeconomics & Outcomes Research|February 14, 2013
Demand-side policies to encourage the use of generic medicines: an overviewPieter Dylst, Arnold Vulto, Steven SimoensPageof 30